School personnel information

写真b

OJI Yuusuke


Keyword

the Wilms' tumor gene, WT1,cancer biology, cancer immunology

Mail Address

Mail Address

URL

http://sahswww.med.osaka-u.ac.jp/~hmtonc/index.html

Organization 【 display / non-display

  • 1997.04.01 - 2003.03.31, Faculty of Medicine, Research Assistant

  • 2003.04.01 - 2004.03.31, Division of Health Sciences, Graduate School of Medicine, Research Assistant

  • 2004.04.01 - 2007.03.31, Division of Health Sciences, Graduate School of Medicine, Associate Professor

  • 2007.04.01 - 2009.03.31, Division of Health Sciences, Graduate School of Medicine, Associate Professor

  • 2009.04.01 - 2010.09.30, Graduate School of Medicine, Professor

  • 2010.10.01 - 2017.03.31, Division of Health Sciences, Graduate School of Medicine, Professor

  • 2017.04.01 - , Division of Health Sciences, Graduate School of Medicine, Professor

Education 【 display / non-display

Osaka University Faculty of Medicine  Graduated M.D. 1990.03
Osaka University Faculty of Medicine  Graduated 1994.06

Employment Record 【 display / non-display

Osaka University Graduate School of Medicine Associate Professor 2004.04 -

Research topics 【 display / non-display

  • Tumor Biology

  • Cancer immunology

Academic Society Membership 【 display / non-display

  • SIHDS

 

Academic Papers 【 display / non-display

  • Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments.. , Nishida S, Tsuboi A, Tanemura A, Ito T, Nakajima H, Shirakata T, Morimoto S, Fujiki F, Hosen N, Oji Y, Kumanogoh A, Kawase I, Oka Y, Azuma I, Morita S, Sugiyama H., Medicine (Baltimore), 2019 Aug;98(33):e16771. 1., 2019.08, Papers

  • What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia., Nakata J, Oji Y, Oka Y, Sugiyama H., Expert Rev Hematol,12: 211-213, 2019, 2019.04, Papers

  • What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia, Nakata J, Oji Y, Oka Y, Sugiyama H, Expert Review of Hematology,12(4) 211-213, 2019.04, Papers

  • A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma, Tsuboi A. , et al., Cancer Immunology, Immunotherapy,68(2) 331-340, 2019.02, Papers

  • A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. , Tsuboi A, Hashimoto N, Fujiki F, Morimoto S, Kagawa N, Nakajima H, Hosen N, Nishida S, Nakata J, Morita S, Sakamoto J, Oji Y, Oka Y, Sugiyama H. , Cancer Immunol Immunother., 2018.11, Papers

display all >>